A Fluorescent Silver(I) Carbene Complex with Anticancer Properties: Synthesis, Characterization, and Biological Studies

Models, Molecular Dose-Response Relationship, Drug Molecular Structure Cell Survival Silver Compounds Antineoplastic Agents Crystallography, X-Ray 01 natural sciences 0104 chemical sciences Structure-Activity Relationship Organometallic Compounds Tumor Cells, Cultured Humans anticancer drugs; fluorescence; mass spectrometry; silver carbene complexes; thioredoxin reductase Drug Screening Assays, Antitumor anticancer drugs; fluorescence; mass spectrometry; silver carbene complexes; thioredoxin reductase; Methane Cell Proliferation Fluorescent Dyes
DOI: 10.1002/cmdc.201800672 Publication Date: 2018-11-16T19:23:50Z
ABSTRACT
AbstractThe silver(I)N‐heterocyclic carbene (NHC) complex bis(1‐(anthracen‐9‐ylmethyl)‐3‐ethylimidazol‐2‐ylidene) silver chloride ([Ag(EIA)2]Cl), bearing two anthracenyl fluorescent probes, has been synthesized and characterized. [Ag(EIA)2]Cl is stable in organic solvents and under physiological conditions, and shows potent cytotoxic effects in vitro toward human SH‐SY5Y neuroblastoma cells. The interactions of [Ag(EIA)2]Cl with a few model biological targets have been studied as well as its ability to be internalized in cells. The in vitro anticancer activity is apparently related to the level of drug internalization. Notably, [Ag(EIA)2]Cl does not react with a few model proteins, but is capable of binding the C‐terminal dodecapeptide of thioredoxin reductase hTrxR(488–499) and to strongly inhibit the activity of this enzyme. Binding occurs through an unconventional process leading to covalent binding of one or two carbene ligands to the C‐terminal dodecapeptide with concomitant release of the silver cation. To the best of our knowledge, this mode of interaction is reported here for the first time for Ag(NHC)2complexes.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (39)